Big Pharma Stock Unappreciated by Analysts Is a Top Performer
- Eli Lilly shares have gained 149 percent since September 2010
- Less than half of analysts rated stock "buy" over last decade
This article is for subscribers only.
Eli Lilly & Co. has been one of the drug industry’s least-loved stocks by industry analysts. That was the wrong call.
Lilly’s shares have been on a five-year rally, helped by the company’s growing portfolio of diabetes medications and bets on cancer and Alzheimer’s disease.